1. Home
  2. MLYS vs VINP Comparison

MLYS vs VINP Comparison

Compare MLYS & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.91

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Vinci Partners Investments Ltd.

VINP

Vinci Partners Investments Ltd.

HOLD

Current Price

$9.58

Market Cap

638.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
VINP
Founded
2019
2009
Country
United States
Brazil
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
638.8M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
MLYS
VINP
Price
$25.91
$9.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$48.67
$14.00
AVG Volume (30 Days)
2.0M
62.8K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
5.72%
EPS Growth
37.43
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$18.07
Revenue Next Year
N/A
$12.74
P/E Ratio
N/A
$24.41
Revenue Growth
N/A
N/A
52 Week Low
$12.59
$9.20
52 Week High
$47.65
$13.61

Technical Indicators

Market Signals
Indicator
MLYS
VINP
Relative Strength Index (RSI) 49.53 42.09
Support Level $25.40 $9.66
Resistance Level $30.85 $10.88
Average True Range (ATR) 1.17 0.37
MACD 0.28 0.01
Stochastic Oscillator 81.88 19.34

Price Performance

Historical Comparison
MLYS
VINP

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About VINP Vinci Partners Investments Ltd.

Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.

Share on Social Networks: